Seek GP advice if cold intolerance is severe, worsening, or accompanied by fatigue, hair loss, or other thyroid dysfunction symptoms
But longer-term studies following patients with Type 2 diabetes found that a significant portion of these patients were also losing weight, and that kind of spurred the interest of using it as a weight-loss drug. The new weight-loss prescriptions fall collectively under the generic identity of semaglutide
STEP-2 - 1.0 mg vs 2.4 mg dose comparison
Pre-Approval Clinical Trial Data The clinical trials that led to FDA approval showed: High rates of nausea, vomiting, and abdominal pain among participants Documented cases of severe gastrointestinal issues requiring medical treatment Evidence that slowed gastric emptying persisted in some patients Reports of adverse event reports related to digestive system paralysis Despite this significant evidence from clinical trials, Novo Nordisks labeling focused on common, temporary side effects while failing to warn patients about the risk of permanent gastroparesis
Lifestyle factors: I walk daily (1012k steps, half of which is a dedicated walk)
